Table 1 Characteristics of the cohort
Hematological malignancies—numbers (%) | Entire cohort—n (%) | PYs of follow-up—n (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
All cases | Lymphoid | All myeloid malignancies and AL | Histio. and dendritic cell | Unsp. | |||||
All* | HL | NHL | |||||||
Overall | 790 (100) | 578 (73.2) | 190 (24.1) | 387 (49.0) | 203 (25.7) | 6 (0.8) | 3 (0.4) | 876,771 (100) | 6,863,833 (100) |
Sex | |||||||||
Male | 466 (59.0) | 343 (59.3) | 117 (61.6) | 226 (58.4) | 118 (58.1) | 3 (50.0) | 2 (66.7) | 491,426 (56.0) | 3,826,559 (55.7) |
Female | 324 (41.0) | 235 (29.7) | 73 (38.4) | 161 (41.6) | 85 (41.9) | 3 (50.0) | 1 (33.3) | 385,345 (44) | 3,037,274 (44.3) |
Age at first CT (years) | |||||||||
<1 | 93 (11.8) | 70 (12.1) | 12 (6.3) | 58 (15) | 22 (10.8) | 0 (0) | 1 (33.3) | 100,628 (11.5) | 789,500 (11.5) |
1 to <5 | 126 (15.9) | 95 (16.4) | 13 (6.8) | 82 (21.2) | 30 (14.8) | 1 (16.7) | 0 (0) | 149,483 (17.0) | 1,159,795 (16.9) |
5 to <10 | 132 (16.7) | 98 (17.0) | 31 (16.3) | 67 (17.3) | 33 (16.3) | 1 (16.7) | 0 (0) | 168,135 (19.2) | 1,308,483 (19.1) |
10 to <15 | 169 (21.4) | 123 (21.3) | 58 (30.5) | 65 (16.8) | 42 (20.7) | 3 (50.0) | 1 (33.3) | 190,561 (21.7) | 1,525,680 (22.2) |
≥15 | 270 (34.2) | 192 (33.2) | 76 (40.0) | 115 (29.7) | 76 (37.4) | 1 (16.7) | 1 (33.3) | 267,964 (30.6) | 2,080,375 (30.3) |
Years since first CT examination at end of follow-up | |||||||||
2 to <5 | 266 (33.7) | 197 (34.1) | 55 (28.9) | 142 (36.7) | 64 (31.5) | 4 (66.7) | 1 (33.3) | 215,041 (24.5) | 323,031 (4.7) |
5 to <10 | 263 (33.3) | 196 (33.9) | 71 (37.4) | 124 (32.0) | 67 (33.0) | 0 (0) | 0 (0) | 305,667 (34.9) | 1,624,031 (23.7) |
10 to <15 | 137 (17.3) | 99 (17.1) | 42 (22.1) | 57 (14.7) | 35 (17.2) | 2 (33.3) | 1 (33.3) | 188,762 (21.5) | 1,938,588 (28.2) |
≥15 | 124 (15.7) | 86 (14.9) | 22 (11.6) | 64 (16.5) | 37 (18.2) | 0 (0) | 1 (33.3) | 167,301 (19.1) | 2,978,183 (43.4) |
Birth cohort | |||||||||
<1980 | 162 (20.5) | 115 (19.9) | 42 (22.1) | 73 (18.9) | 45 (22.2) | 2 (33.3) | 0 (0) | 65,725 (7.5) | 1,169,822 (17.0) |
1980 to <1985 | 143 (18.1) | 94 (16.3) | 41 (21.6) | 53 (13.7) | 47 (23.2) | 0 (0) | 2 (66.7) | 84,747 (9.7) | 1,101,016 (16.0) |
1985 to <1990 | 144 (18.2) | 108 (18.7) | 42 (22.1) | 65 (16.8) | 35 (17.2) | 1 (16.7) | 0 (0) | 152,209 (17.4) | 1,434,265 (20.9) |
1990 to <1995 | 148 (18.7) | 113 (19.6) | 42 (22.1) | 71 (18.3) | 34 (16.7) | 1 (16.7) | 0 (0) | 189,513 (21.6) | 1,303,426 (19.0) |
1995 to <2000 | 107 (13.5) | 81 (14) | 17 (8.9) | 64 (16.5) | 24 (11.8) | 1 (16.7) | 1 (33.3) | 163,306 (18.6) | 989,004 (14.4) |
2000 to <2005 | 67 (8.5) | 55 (9.5) | 6 (3.2) | 49 (12.7) | 11 (5.4) | 1 (16.7) | 0 (0) | 131,115 (15.0) | 643,601 (9.4) |
≥2005 | 19 (2.4) | 12 (2.1) | 0 (0) | 12 (3.1) | 7 (3.4) | 0 (0) | 0 (0) | 90,156 (10.3) | 222,700 (3.2) |
Attained age, years | |||||||||
2 to <20 | 404 (51.1) | 299 (51.7) | 75 (39.5) | 224 (57.9) | 99 (48.8) | 5 (83.3) | 1 (33.3) | 435,894 (49.7) | 2,132,791 (31.1) |
20 to <30 | 295 (37.3) | 214 (37) | 97 (51.1) | 116 (30.0) | 78 (38.4) | 1 (16.7) | 2 (66.7) | 320,706 (36.6) | 2,752,949 (40.1) |
30 to <40 | 86 (10.9) | 62 (10.7) | 18 (9.5) | 44 (11.4) | 24 (11.8) | 0 (0) | 0 (0) | 104,767 (11.9) | 1,633,680 (23.8) |
≥40 | 5 (0.6) | 3 (0.5) | 0 (0) | 3 (0.8) | 2 (1.0) | 0 (0) | 0 (0) | 15,404 (1.8) | 344,414 (5.0) |
Country | |||||||||
Belgium | 5 (0.6) | 3 (0.5) | 0 (0) | 3 (0.8) | 2 (1.0) | 0 (0) | 0 (0) | 9,052 (1.0) | 28,131 (0.4) |
Denmark | 8 (1.0) | 7 (1.2) | 2 (1.1) | 5 (1.3) | 0 (0) | 1 (16.7) | 0 (0) | 15,835 (1.8) | 68,053 (1.0) |
France | 47 (5.9) | 43 (7.4) | 8 (4.2) | 35 (9) | 4 (2.0) | 0 (0) | 0 (0) | 104,542 (11.9) | 453,713 (6.6) |
Germany | 23 (2.9) | 19 (3.3) | 2 (1.1) | 17 (4.4) | 4 (2.0) | 0 (0) | 0 (0) | 39,501 (4.5) | 162,615 (2.4) |
The Netherlands | 137 (17.3) | 98 (17) | 30 (15.8) | 68 (17.6) | 37 (18.2) | 2 (33.3) | 0 (0) | 141,294 (16.1) | 1,201,627 (17.5) |
Norway | 48 (6.1) | 36 (6.2) | 13 (6.8) | 23 (5.9) | 11 (5.4) | 1 (16.7) | 0 (0) | 70,942 (8.1) | 461,963 (6.7) |
Spain | 21 (2.7) | 17 (2.9) | 8 (4.2) | 9 (2.3) | 4 (2.0) | 0 (0) | 0 (0) | 67,031 (7.6) | 253,968 (3.7) |
Sweden | 107 (13.5) | 79 (13.7) | 27 (14.2) | 51 (13.2) | 27 (13.3) | 1 (16.7) | 0 (0) | 119,056 (13.6) | 1,151,088 (16.8) |
United Kingdom | 394 (49.9) | 276 (47.8) | 100 (52.6) | 176 (45.5) | 114 (56.2) | 1 (16.7) | 3 (100) | 309,518 (35.3) | 3,082,675 (44.9) |
Mean bone marrow dose (min–max), mGy | |||||||||
20 (0–286) | 20 (0–286) | 17 (0–209) | 22 (0–286) | 19 (0–117) | 10 (6–22) | 19 (13–25) | 15.6 (0–1,684) | ||
